加科思-B(01167.HK) 公布,其自主研发的泛KRAS抑制剂“JAB-23E73”在中国完成I/IIa期临床试验首例患者给药。加科思表示,KRAS广泛存在于多种肿瘤突变,约23%至25%的癌症患者带有KRAS突变,全球每年新增约270万带有KRAS相关突变的肿瘤患者有望从泛KRAS抑制剂中获益。至于“JAB-23E73”可同时抑制KRAS的活性及非活性状态的KRAS,并对HRAS、NRAS无...
Source Link加科思-B(01167.HK) 公布,其自主研发的泛KRAS抑制剂“JAB-23E73”在中国完成I/IIa期临床试验首例患者给药。加科思表示,KRAS广泛存在于多种肿瘤突变,约23%至25%的癌症患者带有KRAS突变,全球每年新增约270万带有KRAS相关突变的肿瘤患者有望从泛KRAS抑制剂中获益。至于“JAB-23E73”可同时抑制KRAS的活性及非活性状态的KRAS,并对HRAS、NRAS无...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.